{"title":"<i>NOD2</i> Polymorphisms and Their Association with Colorectal Cancer Risk: An Updated Systematic Review and Meta-Analysis.","authors":"Mohamad Ayub Khan Sharzehan, Hilary Sito, Md Asiful Islam, Rahman Jamal, Shing Cheng Tan","doi":"10.3390/cancers17121999","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Nucleotide-binding oligomerization domain-containing protein 2, encoded by <i>NOD2</i>, can trigger chronic gut inflammation that leads to colorectal cancer (CRC). However, studies that have investigated the association of <i>NOD2</i> polymorphisms and CRC susceptibility have produced inconsistent findings. To clarify this relationship, a meta-analysis was conducted to integrate data from previous studies to achieve a more precise evaluation of the risk association. <b>Methods:</b> PubMed, Scopus, and Web of Science databases were systematically searched to identify relevant studies on the association of <i>NOD2</i> polymorphisms with CRC risk. Genetic risk association was quantitatively assessed under five genetic models: homozygous, heterozygous, dominant, recessive, and allele. Thirteen studies, comprising 5,013 cases and 4,463 controls, were included in this study. Four <i>NOD2</i> polymorphisms were investigated in these studies, namely rs2066842, rs2066844, rs2066845, and rs2066847. <b>Results:</b> Of these, only rs2066845 and rs2066847 were found to be significantly associated with increased CRC risk (rs2066845, heterozygous OR = 1.544, 95% CI = 1.014-2.349, P = 0.043; dominant OR = 1.561, 95% CI = 1.035-2.354, P = 0.034; allele OR = 1.572, 95% CI = 1.040-2.375, P = 0.032; rs2066847, heterozygous OR = 1.321, 95% CI = 1.060-1.647, P = 0.013; dominant OR = 1.402, 95% CI = 1.147-1.713, P = 0.001; allele OR = 1.345, 95% CI = 1.088-1.663, P = 0.006). <b>Conclusions:</b> In conclusion, the <i>NOD2</i> rs2066845 and rs2066847 polymorphisms are associated with an increased risk of CRC and may potentially serve as predisposition biomarkers for the cancer.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190208/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17121999","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Nucleotide-binding oligomerization domain-containing protein 2, encoded by NOD2, can trigger chronic gut inflammation that leads to colorectal cancer (CRC). However, studies that have investigated the association of NOD2 polymorphisms and CRC susceptibility have produced inconsistent findings. To clarify this relationship, a meta-analysis was conducted to integrate data from previous studies to achieve a more precise evaluation of the risk association. Methods: PubMed, Scopus, and Web of Science databases were systematically searched to identify relevant studies on the association of NOD2 polymorphisms with CRC risk. Genetic risk association was quantitatively assessed under five genetic models: homozygous, heterozygous, dominant, recessive, and allele. Thirteen studies, comprising 5,013 cases and 4,463 controls, were included in this study. Four NOD2 polymorphisms were investigated in these studies, namely rs2066842, rs2066844, rs2066845, and rs2066847. Results: Of these, only rs2066845 and rs2066847 were found to be significantly associated with increased CRC risk (rs2066845, heterozygous OR = 1.544, 95% CI = 1.014-2.349, P = 0.043; dominant OR = 1.561, 95% CI = 1.035-2.354, P = 0.034; allele OR = 1.572, 95% CI = 1.040-2.375, P = 0.032; rs2066847, heterozygous OR = 1.321, 95% CI = 1.060-1.647, P = 0.013; dominant OR = 1.402, 95% CI = 1.147-1.713, P = 0.001; allele OR = 1.345, 95% CI = 1.088-1.663, P = 0.006). Conclusions: In conclusion, the NOD2 rs2066845 and rs2066847 polymorphisms are associated with an increased risk of CRC and may potentially serve as predisposition biomarkers for the cancer.
背景:由NOD2编码的核苷酸结合寡聚化结构域蛋白2可引发导致结直肠癌(CRC)的慢性肠道炎症。然而,研究NOD2多态性与结直肠癌易感性之间关系的研究得出了不一致的结果。为了澄清这种关系,我们进行了一项荟萃分析,整合了以往研究的数据,以更准确地评估风险相关性。方法:系统检索PubMed、Scopus和Web of Science数据库,寻找NOD2多态性与结直肠癌风险关联的相关研究。在纯合子、杂合子、显性、隐性和等位基因五种遗传模型下定量评估遗传风险关联。本研究纳入13项研究,包括5013例病例和4463例对照。这些研究调查了4个NOD2多态性,分别是rs2066842、rs2066844、rs2066845和rs2066847。结果:其中,只有rs2066845和rs2066847与CRC风险增加显著相关(rs2066845,杂合OR = 1.544, 95% CI = 1.014-2.349, P = 0.043;显性OR = 1.561, 95% CI = 1.035-2.354, P = 0.034;等位基因OR = 1.572, 95% CI = 1.040 ~ 2.375, P = 0.032;rs2066847,杂合子OR = 1.321, 95% CI = 1.060-1.647, P = 0.013;显性OR = 1.402, 95% CI = 1.147 ~ 1.713, P = 0.001;OR = 1.345, 95% CI = 1.088 ~ 1.663, P = 0.006)。结论:总之,NOD2 rs2066845和rs2066847多态性与CRC风险增加相关,可能作为癌症易感性生物标志物。
期刊介绍:
Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.